Drug Profile
Tc-99m-annexin V-128
Alternative Names: 99mTc-rhAnnexin V-128; 99mTechnetium-labelled rhAnnexin V-128; rhAnnexin V-128; Tc-99m-recombinant human annexin V-128; Tc-99m-rhAnnexin V-128Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Atreus Pharmaceuticals
- Developer Advanced Accelerator Applications; INSERM
- Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ankylosing spondylitis; Autoimmune disorders; Cancer; Cardiomyopathies; Cardiovascular disorders; Carotid stenosis; Rheumatoid arthritis; Spondylarthritis
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Rheumatoid arthritis (Diagnosis, In volunteers) in Canada (IV)
- 29 Sep 2021 Discontinued - Phase-I/II for Ankylosing spondylitis (Diagnosis) in Switzerland (IV)
- 29 Sep 2021 Discontinued - Phase-I/II for Cardiovascular disorders (Diagnosis) in France (IV)